Asian pharmaceutical stocks are facing a significant downturn following President Trump's announcement of a 100% tariff on patented drugs, set to take effect on October 1. This move raises concerns about the impact on drug prices and availability, especially for companies that haven't established manufacturing plants in the U.S. The decision could reshape the pharmaceutical landscape, affecting both investors and consumers.

President Trump's proposed 100% tariff on branded and patented drugs is raising alarms in the pharmaceutical industry, particularly for companies lacking US manufacturing capabilities. This move could significantly increase costs for these firms, putting additional pressure on them to establish domestic production. The implications of this tariff could reshape the landscape of drug manufacturing in the US, affecting prices and availability for consumers.

Pharmaceutical stocks in Asia have taken a hit following President Trump's announcement of a 100% tariff on certain imports. This decision has raised concerns among investors about the potential impact on the pharmaceutical industry and the broader economy. As tariffs can lead to increased costs and reduced competitiveness, many are watching closely to see how this will affect market dynamics and healthcare access in the region.